Aardvark Therapeutics - AARD Total Company Value-to-Revenue Ratio

Public company logo of aardvarktherapeutics.com (AARD)

Patent protection for TAS2R agonists and strict FDA regulations create a robust barrier to entry for competitors. The current enterprise value-to-revenue ratio confirms this resilience, with the metric standing at 0.00. Aardvark Therapeutics Inc (AARD) bases its growth foundation on R&D in intestinal receptors, while the high value of therapies for rare pathologies allows the company to exercise pricing power and set premium prices for its products.

AARD Aardvark Therapeutics Inc: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

Aardvark Therapeutics Inc. - analytical breakdowns and key metrics (AARD)

- money and cash flow information:
Initial company analysis:Aardvark Therapeutics Inc AARD
Mass-produced product of Aardvark Therapeutics

For Aardvark Therapeutics Inc (AARD), which utilizes outsourced small molecule production, this metric assesses capitalization efficiency excluding debt load. The indicator sums the market value of shares and net debt, dividing the result by sales volume. The current value of 0.00 for the Enterprise Value to Sales ratio reflects market expectations for future revenues. The Enterprise Value to Sales trend filters out short-term liquidity fluctuations. Excessive growth in this ratio signals that assets are overvalued.

Competitor analysis for Aardvark Therapeutics Inc

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|Company Value to Revenue GPCR|Enterprise Value-to-Revenue Multiple MiMedx MDXG|Enterprise Value-to-Revenue Ratio Rezolute Corp (RZLT)|Company Value to Revenue Lexicon Corp LXRX|Enterprise Value-to-Revenue Ratio MBX Biosciences, Inc. MBX|EV/Sales Multiple altimmune.com ALT|SGMT: Company Value to Revenue|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)